Literature DB >> 31696017

Deacylation of Echinocandin B by Streptomyces species: a novel method for the production of Echinocandin B nucleus.

M C Shivakumar1,2, S Manohar1, B Ishwar1, P Raghu1, J Savitha2.   

Abstract

Anidulafungin, a new class of antifungal agent used for the treatment of chronic fungal infections, is derived from Echinocandin B nucleus, an intermediate metabolite of Echinocandin B produced by Aspergillus nidulans. The enzyme acylase plays a key role in the bioconversion of Echinocandin B to Echinocandin B nucleus. In the present study, a rapid screening method was used to select an actinomycete capable of producing Echinocandin B acylase. Out of 140 actinomycetes screened for the production of acylase by preliminary qualitative plate assay, 53 were selected. The selected isolates were subjected to quantitative assay under submerged fermentation for the bioconversion of Echinocandin B to Echinocandin B nucleus. Among 53 strains of actinomycetes, two strains (BICC-8848 and BICC-8547) exhibited higher degree of acylase activity. Various physico-chemical parameters were optimised for maximum bioconversion of ECB to ECB nucleus. It was found that the conditions viz. pH 7.0, temperature 26 °C and substrate concentration of about 4 g/L supported higher degree of bioconversion. It was also observed that, as the medium volume increased to 500 mL, the conversion rate was also increased by more than two-folds. © King Abdulaziz City for Science and Technology 2019.

Entities:  

Keywords:  Acylase; Anidulafungin; Antifungals; Aspergillus nidulans; Echinocandin B

Year:  2019        PMID: 31696017      PMCID: PMC6811456          DOI: 10.1007/s13205-019-1946-7

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  20 in total

Review 1.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.

Authors:  Nathan P Wiederhold; Russell E Lewis
Journal:  Expert Opin Investig Drugs       Date:  2003-08       Impact factor: 6.206

Review 2.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

3.  Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.

Authors:  J Onishi; M Meinz; J Thompson; J Curotto; S Dreikorn; M Rosenbach; C Douglas; G Abruzzo; A Flattery; L Kong; A Cabello; F Vicente; F Pelaez; M T Diez; I Martin; G Bills; R Giacobbe; A Dombrowski; R Schwartz; S Morris; G Harris; A Tsipouras; K Wilson; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 4.  Echinocandins: role in antifungal therapy, 2005.

Authors:  Aimee K Zaas; Barbara D Alexander
Journal:  Expert Opin Pharmacother       Date:  2005-08       Impact factor: 3.889

Review 5.  The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.

Authors:  Claudia Wagner; Wolfgang Graninger; Elisabeth Presterl; Christian Joukhadar
Journal:  Pharmacology       Date:  2006-10-17       Impact factor: 2.547

6.  Characterization of a nitrilase from Arthrobacter aurescens CYC705 for synthesis of iminodiacetic acid.

Authors:  Wenwen Cai; Erzheng Su; Shujing Zhu; Yuhong Ren; Dongzhi Wei
Journal:  J Gen Appl Microbiol       Date:  2014       Impact factor: 1.452

Review 7.  Update on echinocandin antifungals.

Authors:  Carol A Kauffman; Peggy L Carver
Journal:  Semin Respir Crit Care Med       Date:  2008-04       Impact factor: 3.119

Review 8.  From natural products to clinically useful antifungals.

Authors:  David Barrett
Journal:  Biochim Biophys Acta       Date:  2002-07-18

Review 9.  Echinocandins: pharmacokinetic and therapeutic issues.

Authors:  John D Cleary
Journal:  Curr Med Res Opin       Date:  2009-07       Impact factor: 2.580

10.  Vanillin production using metabolically engineered Escherichia coli under non-growing conditions.

Authors:  Paolo Barghini; Diana Di Gioia; Fabio Fava; Maurizio Ruzzi
Journal:  Microb Cell Fact       Date:  2007-04-16       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.